FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2503674037> ?p ?o ?g. }

• W2503674037 endingPage "1282" @default.
• W2503674037 startingPage "1272" @default.
• W2503674037 abstract "About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer.We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAF(V600E) mutation. Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had been treated previously with a VEGFR multikinase inhibitor (cohort 2). Patients received vemurafenib 960 mg orally twice daily. The primary endpoint was investigator-assessed best overall response in cohort 1 (confirmed on two assessments 4 weeks or longer apart). Analyses were planned to have a minimum median follow-up of 15 months (data cutoff April 18, 2014) and were done in safety, intention-to-treat, and per-protocol populations. This trial is closed and is registered at ClinicalTrials.gov, number NCT01286753.Between June 23, 2011, and Jan 15, 2013, 51 patients were enrolled to the study, 26 in cohort 1 and 25 in cohort 2. Median duration of follow-up was 18·8 months (IQR 14·2-26·0) in cohort 1 and 12·0 months (6·7-20·3) in cohort 2. Partial responses were recorded in ten of 26 patients in cohort 1 (best overall response 38·5%, 95% CI 20·2-59·4). Grade 3 or 4 adverse events were recorded in 17 (65%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2; the most common grade 3 and 4 adverse events were squamous cell carcinoma of the skin (seven [27%] in cohort 1, five [20%] in cohort 2), lymphopenia (two [8%] in each cohort), and increased γ-glutamyltransferase (one [4%] in cohort 1, three [12%] in cohort 2). Two individuals in cohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related. Serious adverse events were reported for 16 (62%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2.Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. As such, this agent represents a potential new treatment option for these patients.F Hoffmann-La Roche." @default.
• W2503674037 created "2016-08-23" @default.
• W2503674037 creator A5001334189 @default.
• W2503674037 creator A5009392187 @default.
• W2503674037 creator A5021287587 @default.
• W2503674037 creator A5023949142 @default.
• W2503674037 creator A5026698479 @default.
• W2503674037 creator A5061365371 @default.
• W2503674037 creator A5084622735 @default.
• W2503674037 creator A5086245221 @default.
• W2503674037 date "2016-09-01" @default.
• W2503674037 modified "2023-10-13" @default.
• W2503674037 title "Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial" @default.
• W2503674037 cites W1571830205 @default.
• W2503674037 cites W1757407923 @default.
• W2503674037 cites W1967792499 @default.
• W2503674037 cites W1969870912 @default.
• W2503674037 cites W1970314237 @default.
• W2503674037 cites W2024156675 @default.
• W2503674037 cites W2036271984 @default.
• W2503674037 cites W2040642592 @default.
• W2503674037 cites W2045020328 @default.
• W2503674037 cites W2062493935 @default.
• W2503674037 cites W2070563197 @default.
• W2503674037 cites W2087614255 @default.
• W2503674037 cites W2106543129 @default.
• W2503674037 cites W2106695112 @default.
• W2503674037 cites W2118986295 @default.
• W2503674037 cites W2128542677 @default.
• W2503674037 cites W2133354058 @default.
• W2503674037 cites W2155242492 @default.
• W2503674037 cites W2155461614 @default.
• W2503674037 cites W2168076926 @default.
• W2503674037 cites W2170552969 @default.
• W2503674037 cites W2171379946 @default.
• W2503674037 cites W2315170604 @default.
• W2503674037 cites W2402753637 @default.
• W2503674037 doi "https://doi.org/10.1016/s1470-2045(16)30166-8" @default.
• W2503674037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5532535" @default.
• W2503674037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27460442" @default.
• W2503674037 hasPublicationYear "2016" @default.
• W2503674037 type Work @default.
• W2503674037 sameAs 2503674037 @default.
• W2503674037 citedByCount "267" @default.
• W2503674037 countsByYear W25036740372016 @default.
• W2503674037 countsByYear W25036740372017 @default.
• W2503674037 countsByYear W25036740372018 @default.
• W2503674037 countsByYear W25036740372019 @default.
• W2503674037 countsByYear W25036740372020 @default.
• W2503674037 countsByYear W25036740372021 @default.
• W2503674037 countsByYear W25036740372022 @default.
• W2503674037 countsByYear W25036740372023 @default.
• W2503674037 crossrefType "journal-article" @default.
• W2503674037 hasAuthorship W2503674037A5001334189 @default.
• W2503674037 hasAuthorship W2503674037A5009392187 @default.
• W2503674037 hasAuthorship W2503674037A5021287587 @default.
• W2503674037 hasAuthorship W2503674037A5023949142 @default.
• W2503674037 hasAuthorship W2503674037A5026698479 @default.
• W2503674037 hasAuthorship W2503674037A5061365371 @default.
• W2503674037 hasAuthorship W2503674037A5084622735 @default.
• W2503674037 hasAuthorship W2503674037A5086245221 @default.
• W2503674037 hasBestOaLocation W25036740372 @default.
• W2503674037 hasConcept C121332964 @default.
• W2503674037 hasConcept C121608353 @default.
• W2503674037 hasConcept C126322002 @default.
• W2503674037 hasConcept C141071460 @default.
• W2503674037 hasConcept C142424586 @default.
• W2503674037 hasConcept C143998085 @default.
• W2503674037 hasConcept C203092338 @default.
• W2503674037 hasConcept C2776131300 @default.
• W2503674037 hasConcept C2779761222 @default.
• W2503674037 hasConcept C2781461381 @default.
• W2503674037 hasConcept C2994587330 @default.
• W2503674037 hasConcept C31760486 @default.
• W2503674037 hasConcept C526584372 @default.
• W2503674037 hasConcept C535046627 @default.
• W2503674037 hasConcept C71924100 @default.
• W2503674037 hasConcept C72563966 @default.
• W2503674037 hasConcept C87355193 @default.
• W2503674037 hasConcept C90924648 @default.
• W2503674037 hasConceptScore W2503674037C121332964 @default.
• W2503674037 hasConceptScore W2503674037C121608353 @default.
• W2503674037 hasConceptScore W2503674037C126322002 @default.
• W2503674037 hasConceptScore W2503674037C141071460 @default.
• W2503674037 hasConceptScore W2503674037C142424586 @default.
• W2503674037 hasConceptScore W2503674037C143998085 @default.
• W2503674037 hasConceptScore W2503674037C203092338 @default.
• W2503674037 hasConceptScore W2503674037C2776131300 @default.
• W2503674037 hasConceptScore W2503674037C2779761222 @default.
• W2503674037 hasConceptScore W2503674037C2781461381 @default.
• W2503674037 hasConceptScore W2503674037C2994587330 @default.
• W2503674037 hasConceptScore W2503674037C31760486 @default.
• W2503674037 hasConceptScore W2503674037C526584372 @default.
• W2503674037 hasConceptScore W2503674037C535046627 @default.
• W2503674037 hasConceptScore W2503674037C71924100 @default.
• W2503674037 hasConceptScore W2503674037C72563966 @default.
• W2503674037 hasConceptScore W2503674037C87355193 @default.
• W2503674037 hasConceptScore W2503674037C90924648 @default.

• next